Prognostic and Therapeutic Applications of RKIP in Cancer
- 1st Edition - February 5, 2020
- Editors: Benjamin Bonavida, Stavroula Baritaki
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 9 6 1 2 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 4 5 1 - 9
Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expressio… Read more
Purchase options
Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students.
- Provides an update from experts in the field on diagnostics, prognostics and therapeutics
- Brings a clear overview of recent findings and references, as well as summaries, significant molecular pathways, and conclusions in each chapter
- Provides a general introductory chapter on contributions in the field and a chapter summary, with synthesized findings and a projection of future goals
Cancer researchers, medical scientists, clinicians, graduate students
1. RKIP: General Properties in Human MalignanciesInsight on the Role of RKIP in Cancer through Key Protein Partners and Cellular ProtrusionsFrancoise Schoentgen2. Function of BACH1 as a key target of RKIP in Breast CancerMarsha Rich Rosner & Jiyoung Lee3. Pleiotropic Activities of RKIP in Cancer: Role in Survival, EMT, Chemo-immuno-resistance, and AutophagyYuhao Wang & Benjamin Bonavida4. Role of RKIP in the Tumor Response to Photo-oxidative DamageValentina Rapozzi & Luigi Emilio Xodo5. A Review of RKIP Promotion of Tumour Progression, Metastasis and Poor Outcome in Multiple Solid Tumour TypesSharon Glynn, Eoin Dervan, & Dibyangana Bhattacharyya6. Tumor hypoxic stress, cellular plasticity and RKIPSalem Chouaib, Stéphane Terry, Stéphanie Buart, & Abérémane Abdou7. RKIP in Uterine TissuesPasquapina Ciarmela8. The Role of RAF Kinase Inhibitor Protein in Hematologic MalignanciesArmin Zebisch9. RKIP Regulation and Crosstalks Regulation of RKIP Expression in Breast Cancer Cells by miRNAKam Yeung, Julius Castro, Hussain N. Odeh, Christopher Figy, Miranda L. Yeung, & Robert Trumbly10. The Master Cellular Regulators “RKIP & GSK3β”: Their Interactions and Repercussions on CancerMira Bosso & Fahd Al-Mulla11. Identification of Regulatory Crosstalks between RKIP and BCRA1 Tumor Suppressors in Healthy Tissues and Cancer (Breast and Ovarian): Therapeutic ImplicationsMartina Rama & Benjamin Bonavida12. RKIP a Master of Regulatory Pathways: PerspectivesKhosrow Kashfi, Yongxin Zhou, & Gabrielle M. Corrente13. Local and Systemic Endothelial Dysfunction in Cancer: RKIP-Mimetic, Therapy of Cancer and Endothelium-SafetyMarta Smeda, Marek Grosicki, & Stefan Chlopicki14. Stochastic Modeling for Investigation of Regulation of Transcription of RKIP geneAlexandre Ramos, Leonardo dos Reis Gama, Mauro César Cafundó Morais, & Poliana Cristina de Melo Martins15. Anti-cancer effect of RKIP via modulating autophagy during metastasisDeok Ryong Kim & Mahmoud Ahmed16. RKIP and Inflammation The Role of Raf Kinase Inhibitory Protein in InflammationSteve Shenouda, Fahd Al-Mulla, Mira Bosso,& Rasheed Ahmad17. Role of RKIP in inflammatory responsesXiaojian Wang & Wenlong Lin18. RKIP: Prognostic and Therapeutic Implications RKIP in Human Diseases and its Potential as a Prognostic Indicator and Therapeutic TargetApostolos Zaravinos & Theodoulakis Christofi19. Therapeutic Targeting of SNAIL, RKIP and YY1 in Tumor Metastasis and Drug ResistanceNadire Özenver & Thomas Efferth20. Implications of RKIP protein in cancer prognosis and therapy response: a literature updateDiana Cardoso-Carneiro, Ana Raquel-Cunha, Joana Pinheiro, Maria Gabriela-Freitas, Patrícia Fontão, Rui M. Reis, & Olga Martinho21. Theranostic Role of RKIP in CancerGanji Purnachandra Nagaraju, Begum Dariya, Gayathri Chalikonda, & Afroz Alam22. Downregulation of the Raf Kinase Inhibitory Protein (RKIP) in Clear Cell Renal Cell Carcinoma Associates with Poor PrognosisDamu Tang Anil Kapoor, Xiaozeng Lin, David Rodrig
- Edition: 1
- Published: February 5, 2020
- Language: English
BB
Benjamin Bonavida
Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Affiliations and expertise
Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USASB
Stavroula Baritaki
Stavroula Baritaki’s, PhD, is currently Professor in Experimental Oncology at the University of Greece,. Her areas of expertise include the understanding of the molecular mechanisms involved in tumour cell therapeutic resistance and acquisition of a metastatic phenotype. Her studies have revealed novel gene products, including Raf-1 Kinase inhibitory protein (RKIP),. Followed by further studies on the epigenetic and post-translational regulation of RKIP in many cancer types, her overall findings have firstly suggested the RKIP downregulation in cancer cells as a putative gene signature of tumor chemo/immune-resistance and EMT with prognostic and therapeutic significance in an individualized basis. On this context, Dr. Baritaki has extended her research interests in identifying novel agents that through RKIP induction are able to inhibit EMT or improve either the host immunosurveillance and/or the efficacy of anti-tumor therapies, especially if they are combined with conventional immuno-stimulatory or chemotherapeutic regimens. Most of these agents are currently under clinical trials.
Affiliations and expertise
Division of Surgical Oncology, School of Medicine, University of Crete, Heraklion, Crete, GreeceRead Prognostic and Therapeutic Applications of RKIP in Cancer on ScienceDirect